Author: Kudo, Masatoshi; Kurosaki, Masayuki; Ikeda, Masafumi; Aikata, Hiroshi; Hiraoka, Atsushi; Torimura, Takuji; Sakamoto, Naoya
Title: Treatment of Hepatocellular Carcinoma (HCC) during the COVIDâ€19 Outbreak: The Working Group Report of JAMTTâ€HCC Cord-id: 4zg7zeks Document date: 2020_6_24
ID: 4zg7zeks
Snippet: This contingency guide was formulated on the premise that delivering standard treatment for hepatocellular carcinoma (HCC) has come under strain due to the COVIDâ€19 pandemic. Measures required are likely to vary largely across regions and individual institutions, depending on the level of the strain imposed by the pandemic (e.g., number of inpatients infected with COVIDâ€19 and the availability of resources, including personal protective equipment and inpatient beds). Also, models suggest tha
Document: This contingency guide was formulated on the premise that delivering standard treatment for hepatocellular carcinoma (HCC) has come under strain due to the COVIDâ€19 pandemic. Measures required are likely to vary largely across regions and individual institutions, depending on the level of the strain imposed by the pandemic (e.g., number of inpatients infected with COVIDâ€19 and the availability of resources, including personal protective equipment and inpatient beds). Also, models suggest that second and third waves of COVIDâ€19 will occur before effective vaccines and medicines become widely available in Japan (expected time, 2–3 years). This guide should serve as a good reference for best practices in the management of HCC in light of the possible risk of impending collapse of the healthcare system due to a surge in COVIDâ€19 infections.
Search related documents:
Co phrase search for related documents- active monitoring and liver injury: 1
Co phrase search for related documents, hyperlinks ordered by date